[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Hartmann TB, Bazhin AV, Schadendorf D, Eichmüller SB: SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer; 2005 Mar 10;114(1):88-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.
  • Metastatic melanoma still has a very poor prognosis since it withstands conventional therapies like surgery or chemotherapy.
  • A paraneoplastic autoimmune manifestation of this disease is melanoma-associated retinopathy (MAR).
  • By screening a retina and a melanoma cDNA phage library by SEREX using sera of patients suffering from melanoma and, in some cases, clinical symptoms of MAR, we identified 20 new antigens (HD-MM-28-47), of which 14 clones had high homology to well-known genes.
  • Six of these genes had previously been associated with retina: rhodopsin, visual arrestin, MEK1, SRPX, BBS1 and galectin-3.
  • The expression profile of the antigens identified on the basis of homologous EST database entries in healthy tissues was ubiquitous to differential.
  • Using RT-PCR, we found frequent expression of preselected antigens in melanoma cell lines.
  • Retinal proteins were recognized by serum antibodies of melanoma patients but not healthy controls.
  • [MeSH-major] Antigens, Neoplasm / analysis. Melanoma / immunology. Paraneoplastic Syndromes / immunology. Retinal Diseases / immunology. Serologic Tests / methods. Skin Neoplasms / immunology
  • [MeSH-minor] Blotting, Northern. Cell Line, Tumor. DNA, Complementary / analysis. DNA, Neoplasm / analysis. Gene Library. Humans. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Rhodopsin / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523688.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; 9009-81-8 / Rhodopsin
  •  go-up   go-down


2. Sithanandam G, Anderson LM: The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther; 2008 Jul;15(7):413-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ERBB3 receptor in cancer and cancer gene therapy.
  • Studies of ERBB3 expression in primary cancers and of its mechanistic contributions in cultured cells have implicated it, with varying degrees of certainty, with causation or sustenance of cancers of the breast, ovary, prostate, certain brain cells, retina, melanocytes, colon, pancreas, stomach, oral cavity and lung.
  • Recent results link high ERBB3 activity with escape from therapy targeting other ERBBs in lung and breast cancers.
  • Small inhibitory RNA (siRNA) to ERBB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2005;29(3):249-55 [15936593.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1182-95 [15790591.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4835-42 [16000581.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Jun;14(6):591-606 [16004590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5 [15994225.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):502-10 [15908515.001]
  • [Cites] Glia. 2005 Aug 15;51(3):217-28 [15812817.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):665-84 [16035612.001]
  • [Cites] J Appl Physiol (1985). 2005 Jul;99(1):298-307 [15731393.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5007-18 [16051952.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6967-75 [16061682.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):589-95 [17701904.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):453-7 [17667926.001]
  • [Cites] Structure. 2007 Aug;15(8):942-54 [17697999.001]
  • [Cites] EMBO J. 2007 Sep 5;26(17):3936-44 [17690690.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):851-8 [17786317.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4450-4 [17765895.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(18):2358-77 [17530167.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Sep;7(6):591-604 [17896924.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1349-57 [16170026.001]
  • [Cites] BMC Genomics. 2005;6:109 [16107210.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9082-91 [16199884.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Nov;33(5):490-9 [16055672.001]
  • [Cites] Prostate. 2005 Dec 1;65(4):306-15 [16015604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15224-9 [16203963.001]
  • [Cites] Breast Cancer Res. 2007;9(5):111 [17983482.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):337-44 [17704947.001]
  • [Cites] J Surg Res. 2008 May 1;146(1):43-8 [17631905.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1935-42 [17332320.001]
  • [Cites] Cell Growth Differ. 1996 May;7(5):551-61 [8732665.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Nov;30(11):658-61 [8745489.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 4;226(1):59-69 [8806592.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3663-74 [9851973.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):859-66 [9873025.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1629-34 [9815853.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):305-14 [9927187.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):713-21 [9927298.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):215-21 [10095121.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2149-64 [10205169.001]
  • [Cites] FEBS Lett. 1999 Mar 26;447(2-3):227-31 [10214951.001]
  • [Cites] J Pathol. 2007 Oct;213(2):180-9 [17891747.001]
  • [Cites] Chin Med J (Engl). 2007 Sep 5;120(17):1505-10 [17908459.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):32689-98 [17823122.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2602-11 [17920261.001]
  • [Cites] Trends Mol Med. 2007 Dec;13(12):527-34 [17981505.001]
  • [Cites] J Appl Physiol (1985). 2007 Dec;103(6):2077-83 [17916677.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):73-80 [17962208.001]
  • [Cites] Breast Cancer Res. 2007;9(4):R50 [17686159.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):7-11 [16843261.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10917-22 [16832058.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4372s-4376s [16857813.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4409s-4415s [16857819.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):613-22 [16867224.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:419-26 [16869779.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75 [16896310.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):2051-9 [16928826.001]
  • [Cites] Clin Breast Cancer. 2006 Aug;7(3):254-61 [16942643.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):25-33 [16872715.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):1061-7 [9772300.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1949-57 [9788438.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 29;251(3):903-6 [9791008.001]
  • [Cites] Mol Biol Cell. 1998 Nov;9(11):3195-209 [9802906.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):545-50 [9816014.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1413-20 [9815939.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1385-90 [9823984.001]
  • [Cites] Endocrinology. 1998 Dec;139(12):4756-64 [9832411.001]
  • [Cites] Dev Biol. 1998 Dec 1;204(1):97-110 [9851845.001]
  • [Cites] Scand J Clin Lab Invest. 2006;66(7):623-30 [17101554.001]
  • [Cites] Cell Prolif. 2006 Dec;39(6):563-74 [17109639.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11279-86 [17145873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19063-8 [17148612.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):366-76 [17200208.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):481-6 [10226586.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 May;20(5):914-23 [10226061.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2681-9 [10348342.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3348-58 [10369675.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3440-51 [10376522.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2843-6 [10383144.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2891-7 [10383151.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3503-10 [17173075.001]
  • [Cites] Int J Mol Med. 2007 Jul;20(1):3-10 [17549382.001]
  • [Cites] Nat Med. 2007 Jun;13(6):675-7 [17554333.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1772(7):737-47 [17553674.001]
  • [Cites] BJU Int. 2007 Aug;100(2):303-9 [17532856.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6544-8 [17638862.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):675-84 [17634423.001]
  • [Cites] Microsurgery. 2007;27(5):429-38 [17596863.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4326-30 [17671112.001]
  • [Cites] Genomics. 2007 Sep;90(3):344-53 [17604597.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2763-73 [17652160.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1498-503 [17627612.001]
  • [Cites] J Vet Med Sci. 1998 May;60(5):549-54 [9637286.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1825-36 [9637684.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2803-13 [9652748.001]
  • [Cites] Neurosci Res. 1998 Apr;30(4):351-4 [9678639.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):757-63 [9677338.001]
  • [Cites] Oncogene. 1998 Jun 25;16(25):3243-52 [9681822.001]
  • [Cites] Biochem J. 1998 Aug 15;334 ( Pt 1):189-95 [9693119.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):20996-1002 [9694850.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2727-32 [9703936.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):771-7 [9712416.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):6090-101 [9742126.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26954-61 [9756944.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1874-82 [17266042.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):393-401 [17426253.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1030-41 [17124505.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):517-31 [8615665.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1679-87 [8622888.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1781-8 [8622899.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):5251-7 [8617810.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3884-90 [8632008.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2452-67 [8665853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5958-62 [8650201.001]
  • [Cites] J Pathol. 1996 Feb;178(2):140-5 [8683379.001]
  • [Cites] Prostate. 1996 Jun;28(6):392-405 [8650077.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2623-6 [8669836.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5485-8 [12359757.001]
  • [Cites] Apoptosis. 2002 Dec;7(6):483-91 [12370490.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):931-41 [16097449.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7734-42 [16107719.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5597-604 [16110019.001]
  • [Cites] Prostate. 2005 Oct 1;65(2):130-40 [15880609.001]
  • [Cites] Invest New Drugs. 2005 Oct;23(5):391-409 [16133791.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7525-9 [16140912.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64 [16163160.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R708-18 [16168116.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Mol Biol (Mosk). 2003 Jan-Feb;37(1):97-111 [12624952.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):143-8 [12648669.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):14-30 [12648463.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):54-65 [12648465.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):89-98 [12648468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15024-9 [16203964.001]
  • [Cites] Exp Oncol. 2005 Sep;27(3):225-8 [16244586.001]
  • [Cites] Nucleic Acids Res. 2005;33(18):6024-33 [16254079.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):209-14 [16003751.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Biochemistry. 2005 Dec 6;44(48):15842-57 [16313187.001]
  • [Cites] Biochem J. 2005 Dec 15;392(Pt 3):417-23 [16122376.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6107-18 [8815893.001]
  • [Cites] Pathol Res Pract. 1995 Oct;191(10):973-81 [8838364.001]
  • [Cites] J Pathol. 1996 Aug;179(4):381-5 [8869284.001]
  • [Cites] Cancer Surv. 1996;27:339-49 [8909809.001]
  • [Cites] J Neurosci. 1997 Mar 1;17(5):1642-59 [9030624.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):212-6 [9052472.001]
  • [Cites] Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30 [9072304.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):757-63 [9148746.001]
  • [Cites] Biochem J. 1997 Apr 1;323 ( Pt 1):113-8 [9173868.001]
  • [Cites] Mod Pathol. 1997 Feb;10(2):142-8 [9127320.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12052-6 [9115272.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1319-30 [9137492.001]
  • [Cites] Oncogene. 1997 Jul 24;15(4):473-81 [9242384.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5608-17 [9312020.001]
  • [Cites] Nature. 1997 Oct 16;389(6652):725-30 [9338783.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):187-95 [9365520.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5195-201 [9389501.001]
  • [Cites] Oncogene. 1997 Nov 27;15(22):2705-16 [9400997.001]
  • [Cites] Exp Neurol. 1997 Dec;148(2):604-15 [9417836.001]
  • [Cites] Curr Biol. 1998 Jan 1;8(1):R15-8 [9427620.001]
  • [Cites] Development. 1997 Dec;124(24):4999-5011 [9362461.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):161-7 [9499191.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4539-46 [9494565.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7717-24 [9516479.001]
  • [Cites] Oncogene. 1998 Mar 12;16(10):1249-58 [9546426.001]
  • [Cites] Nature. 1998 May 7;393(6680):83-5 [9590694.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13819-27 [9593726.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):465-72 [15078990.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Chest. 2004 May;125(5 Suppl):141S-4S [15136468.001]
  • [Cites] J Pathol. 2004 Jun;203(2):688-95 [15141384.001]
  • [Cites] Ai Zheng. 2004 May;23(5):568-72 [15142456.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3395-405 [15150091.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Oncogene. 2004 May 27;23(25):4454-65 [15064750.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Curr Pharm Des. 2004;10(15):1739-44 [15180536.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26126-33 [15073182.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):332-6 [15225657.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):27306-16 [16825199.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4317-23 [16896008.001]
  • [Cites] Syst Biol (Stevenage). 2006 Jan;153(1):22-33 [16983832.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1309-15 [17001163.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] BMC Evol Biol. 2006;6:79 [17026767.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2986-7 [16998794.001]
  • [Cites] Pediatr Pulmonol. 2006 Dec;41(12):1205-12 [17063476.001]
  • [Cites] Adv Cancer Res. 2000;77:25-79 [10549355.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6050-62 [10557094.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Dec;21(6):701-9 [10572067.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2358-68 [10582594.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5 [10615931.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4164-74 [10632356.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):63-80 [10653587.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):16-24 [10657694.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]
  • [Cites] J Invest Dermatol. 2007 Feb;127(2):394-9 [16946712.001]
  • [Cites] Nature. 2007 Jan 25;445(7126):437-41 [17206155.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1293-303 [17163417.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1645-52 [17308105.001]
  • [Cites] J Biol Chem. 1996 Jun 7;271(23):13491-6 [8662847.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):229-33 [8688326.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):55-63 [10424781.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2861-78 [10473632.001]
  • [Cites] Exp Neurol. 1999 Oct;159(2):494-503 [10506520.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1010-8 [10512940.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47050-6 [15345710.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):517-27 [15542435.001]
  • [Cites] Thorax. 2004 Dec;59(12):1032-40 [15563701.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):97-107 [15571795.001]
  • [Cites] Cancer Invest. 2004;22(5):706-12 [15581051.001]
  • [Cites] Cancer Invest. 2004;22(6):858-65 [15641483.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1321-6 [15520002.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):140-6 [15583694.001]
  • [Cites] Mol Hum Reprod. 2005 Feb;11(2):133-40 [15591450.001]
  • [Cites] Melanoma Res. 2005 Feb;15(1):21-8 [15714117.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):846-53 [15720812.001]
  • [Cites] J Neurosci Res. 2005 Mar 1;79(5):584-97 [15682390.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8238-47 [15611073.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1778-82 [15753374.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1704-12 [15755991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1847-59 [15688028.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2163-8 [15788662.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1177-85 [15809707.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1670-5 [15751020.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):519-27 [15704104.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4253-60 [15899817.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2597-605 [11135221.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5471-6 [11114724.001]
  • [Cites] Eur Respir J. 2000 Nov;16(5):991-6 [11153605.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100 [11236032.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Cell Physiol. 2001 May;187(2):209-17 [11268000.001]
  • [Cites] Nat Neurosci. 2001 Apr;4(4):374-81 [11276227.001]
  • [Cites] J Comp Neurol. 2001 Apr 23;433(1):86-100 [11283951.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14407-13 [11278550.001]
  • [Cites] Chin Med Sci J. 1997 Jun;12(2):67-70 [11324501.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):185-91 [11325528.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4251-62 [12376557.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4029-44 [12429844.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14843-8 [12411582.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6510-8 [12438245.001]
  • [Cites] J Biochem Mol Toxicol. 2002;16(5):209-19 [12439862.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3933-42 [12473609.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8732-40 [12483526.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1294-301 [12618754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2866-71 [11867753.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):8961-9 [11779863.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Virchows Arch. 2002 May;440(5):476-84 [12021921.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3132-7 [12036925.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3151-8 [12036928.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):929-39 [12045181.001]
  • [Cites] Dev Dyn. 2002 Jul;224(3):356-60 [12112465.001]
  • [Cites] Exp Cell Res. 2003 Apr 1;284(2):291-302 [12651161.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):2168-77 [12682367.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1274-83 [12684395.001]
  • [Cites] Mol Cell Endocrinol. 2003 Mar 28;201(1-2):39-46 [12706292.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1775-81 [12721254.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G996-1005 [12571082.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3205-12 [12761490.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1334-40 [16288303.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11478-85 [16357156.001]
  • [Cites] Urology. 2005 Dec;66(6):1197-202 [16360440.001]
  • [Cites] Nature. 2006 Jan 12;439(7073):168-74 [16273093.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):831-42 [16428439.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):184-8 [16434982.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1418-26 [16452197.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 10):S3-8 [16459173.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89 [16467077.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):17-27 [16267617.001]
  • [Cites] Acta Med Okayama. 2006 Feb;60(1):25-34 [16508686.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Cell Signal. 2006 Jul;18(7):923-33 [16460914.001]
  • [Cites] BMC Cancer. 2006;6:46 [16507107.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1054-67 [16401639.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 9;344(3):859-68 [16631606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2730-7 [16675564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7789-94 [16682621.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Mol Syst Biol. 2005;1:2005.0008 [16729043.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1703-9 [16685269.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):727-34 [16557579.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1137-49 [16777603.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4103-11 [16818711.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L175-80 [16489114.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):323-31 [16765644.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):449-54 [14735192.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):646-53 [14737100.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):135-43 [14739033.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):446-51 [14744754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):923-8 [14732693.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):929-34 [14732694.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4479-89 [14602723.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1197-205 [14647450.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):332-7 [15264245.001]
  • [Cites] Biochim Biophys Acta. 2004 Aug 4;1673(3):194-200 [15279891.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7748-57 [15314180.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7078-85 [15466203.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1489-94 [15492843.001]
  • [Cites] Adv Protein Chem. 2004;68:1-27 [15500857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193-7 [2687875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):4905-9 [2164210.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6 [1715580.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):1116-21 [1333787.001]
  • [Cites] J Pathol. 1992 Nov;168(3):269-73 [1361525.001]
  • [Cites] J Pathol. 1992 Nov;168(3):275-80 [1361526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50 [8383326.001]
  • [Cites] Biochem Biophys Res Commun. 1993 May 14;192(3):1189-97 [7685162.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):935-40 [8335401.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3393-401 [8247542.001]
  • [Cites] Gastroenterology. 1999 Nov;117(5):1119-27 [10535875.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):683-90 [10682683.001]
  • [Cites] Tumour Biol. 2000 Mar-Apr;21(2):105-15 [10686540.001]
  • [Cites] Regul Pept. 2000 Feb 8;87(1-3):73-82 [10710290.001]
  • [Cites] J Cell Biochem. 1999 Jun 15;73(4):522-32 [10733345.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):432-40 [10745024.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1647-56 [10763821.001]
  • [Cites] Cell Growth Differ. 2000 Mar;11(3):173-83 [10768865.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):492-500 [8264617.001]
  • [Cites] J Pathol. 1993 Jul;170(3):271-8 [8133400.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3550-8 [7515147.001]
  • [Cites] EMBO J. 1994 Jun 15;13(12):2831-41 [8026468.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1140-5 [7913137.001]
  • [Cites] FEBS Lett. 1994 Jul 25;349(1):139-43 [8045292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24747-55 [7929151.001]
  • [Cites] Histopathology. 1994 Sep;25(3):247-52 [7821892.001]
  • [Cites] J Neurosci. 1995 Feb;15(2):1329-40 [7869101.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4784-91 [7876251.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7111-6 [7535767.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):758-62 [7710941.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Apr;80(2):100-2 [7736422.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1813-21 [7538656.001]
  • [Cites] J Neurooncol. 1994;22(3):201-7 [7760096.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):202-6 [7622309.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):401-5 [7626487.001]
  • [Cites] Cancer Lett. 1995 Aug 16;95(1-2):79-83 [7656248.001]
  • [Cites] J Biol Chem. 1995 Sep 22;270(38):22608-13 [7673253.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4267-75 [7556068.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6496-505 [8524214.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31119-23 [8537373.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1457-65 [8640840.001]
  • [Cites] Cell Growth Differ. 1995 Dec;6(12):1567-77 [9019162.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6071-6 [8626392.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):471-4 [8615656.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):91-5 [10769639.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):205-11 [10782893.001]
  • [Cites] J Biochem. 2000 May;127(5):925-30 [10788804.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):617-25 [10797281.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):301-13 [10797304.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):321-9 [10797306.001]
  • [Cites] J Mol Evol. 2000 May;50(5):397-412 [10824084.001]
  • [Cites] Biochemistry. 2000 Jul 25;39(29):8503-11 [10913256.001]
  • [Cites] Int J Cancer. 2000 Sep 15;87(6):763-70 [10956383.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):629-41 [10995872.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):30934-42 [10908564.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63 [11062025.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(1):61-9 [11079160.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4217-25 [11106235.001]
  • [Cites] J Allergy Clin Immunol. 2000 Dec;106(6):1124-31 [11112896.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5568-73 [11114736.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):43-52 [11326315.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Biol Reprod. 2001 Jun;64(6):1835-44 [11369616.001]
  • [Cites] Cell Signal. 2001 May;13(5):321-30 [11369513.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4467-73 [11389077.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22685-98 [11297548.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):268-79 [11425269.001]
  • [Cites] Cytometry. 2001 Aug 1;44(4):338-48 [11500850.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5199-209 [11526509.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7184-8 [11585753.001]
  • [Cites] J Pathol. 2001 Oct;195(3):343-8 [11673832.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42153-61 [11546794.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 23;289(1):240-4 [11708806.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44266-74 [11555649.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1868-76 [11789762.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):78-86 [11791178.001]
  • [Cites] Exp Brain Res. 2002 Jan;142(1):81-90 [11797086.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jan;109(1):75-81 [11799369.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4704-12 [11741943.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1159-66 [11850835.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(1):47-57 [11859873.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5609-18 [12165860.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1330-3 [12154198.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Sep;27(3):306-13 [12204892.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):127-37 [12204533.001]
  • [Cites] J Recept Signal Transduct Res. 1999 Nov;19(6):885-908 [10533979.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):697-702 [12209129.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20971-8 [12600989.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3598-607 [12789268.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1711-6 [12663324.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23630-8 [12714585.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1455-60 [12820409.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3764-74 [12839972.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1744-53 [12840049.001]
  • [Cites] J Pathol. 2003 Jul;200(3):290-7 [12845624.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):758-65 [12866037.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8 [12853564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9226-31 [12874383.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35702-9 [12824184.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):736-41 [14514775.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1581-92 [12896906.001]
  • [Cites] Expert Rev Mol Med. 2003 May;5(14):1-11 [14585167.001]
  • [Cites] Med Oral. 2003 Nov-Dec;8(5):374-81 [14595263.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):802-12 [14632199.001]
  • [Cites] Glia. 2004 Jan 15;45(2):197-207 [14730713.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):289-93 [14735165.001]
  • (PMID = 18404164.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01 CO012400; United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 BC005399-24; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuregulins; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, ErbB-3
  • [Number-of-references] 438
  • [Other-IDs] NLM/ NIHMS107476; NLM/ PMC2761714
  •  go-up   go-down


3. De Potter P, Disneur D, Levecq L, Snyers B: [Ocular manifestations of cancer]. J Fr Ophtalmol; 2002 Feb;25(2):194-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Manifestations oculaires des cancers.
  • Cancer may affect the eye and orbit as a direct result of metastatic neoplastic infiltration, compression, or circulating antibodies involving paraneoplastic retinal degeneration.
  • The choroid is the most common site for uveal metastasis; metastases to the ciliary body, iris, retina, optic disk, and vitreous are rare.
  • Approximately one-third of patients have no history of primary cancer at the time of ocular diagnosis.
  • The short-term prognosis for vision is usually good after an individualized therapeutic approach (chemotherapy, hormonal therapy, external beam radiotherapy, or plaque radiotherapy), but the systemic prognosis is poor.
  • The visual paraneoplastic syndromes encompass several distinct clinical and pathological entities including carcinoma-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and bilateral diffuse melanocytic uveal proliferation (BDUMP).
  • Identification of circulating antibodies against retinal proteins (recovering, 23-kDa retinal protein; 46-kDa and 60-kDa retinal proteins) serves to recognize the paraneoplastic nature of the patient's symptoms, which frequently develop before the cancer is diagnosed.
  • Anecdotal therapeutic responses are described after systemic steroids, immunoglobulin injection, and plasmapheresis.
  • [MeSH-major] Eye Neoplasms / secondary. Lymphoma / diagnosis. Paraneoplastic Syndromes
  • [MeSH-minor] Adult. Child. Choroid Neoplasms / diagnosis. Choroid Neoplasms / secondary. Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Eyelid Neoplasms / secondary. Female. Humans. Iris Neoplasms / diagnosis. Iris Neoplasms / secondary. Lymphoma, Non-Hodgkin / diagnosis. Male. Melanoma / complications. Melanoma / diagnosis. Melanoma / secondary. Orbital Neoplasms / diagnosis. Orbital Neoplasms / secondary. Prognosis. Retinal Diseases / etiology. Retinal Neoplasms / diagnosis. Retinal Neoplasms / secondary. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11941243.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 103
  •  go-up   go-down


Advertisement
4. Bishop RJ, Ding X, Heller CK 3rd, Illei G, Caruso R, Cunningham D, Pavletic S, Chan CC: Rapid vision loss associated with fludarabine administration. Retina; 2010 Sep;30(8):1272-7
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A 23-year-old man (Case 1) with systemic lupus erythematosus developed rapid and severe vision loss, generalized neurologic decline, and eventual death after administration of fludarabine before stem cell transplantation.
  • A 48-year-old woman (Case 2) and a 60-year-old man (Case 3), both with metastatic melanoma, had similar courses after receiving fludarabine as part of a preparatory regimen before adoptive cell therapy.
  • In all three cases, serum antiretinal antibodies were negative before and after treatment; electrophysiological testing showed markedly decreased B-waves; and pathologic analysis showed loss of retinal bipolar and ganglion cells, gliosis within the retina and optic nerve, and optic nerve atrophy.
  • CONCLUSION: Fludarabine toxicity can result in severe vision loss attributable to damage to retinal bipolar and ganglion cells.
  • Although effective treatments are not known, care should be taken to consider fludarabine toxicity in patients who present with vision loss approximately 1 month after treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Blindness / chemically induced. Retinal Diseases / chemically induced. Vidarabine / analogs & derivatives
  • [MeSH-minor] Brain Diseases / chemically induced. Brain Diseases / diagnosis. Electroretinography. Evoked Potentials, Visual. Fatal Outcome. Female. Humans. Lupus Erythematosus, Systemic / drug therapy. Magnetic Resonance Imaging. Male. Melanoma / drug therapy. Melanoma / secondary. Middle Aged. Myeloablative Agonists / adverse effects. Retina / drug effects. Retina / physiopathology. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1225-8 [2428492.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5953-8 [2428488.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):74-9 [2416889.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2216-28 [7931492.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Cancer Invest. 1990;8(5):459-65 [2124943.001]
  • [Cites] Ophthalmology. 2004 Mar;111(3):535-9 [15019332.001]
  • (PMID = 20224467.001).
  • [ISSN] 1539-2864
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA EY000222-24; United States / Intramural NIH HHS / / ZIA EY000222-25
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS227991; NLM/ PMC2943138
  •  go-up   go-down


5. Dawson WW, Jordan BL, Marsh RD, Hazariwala K, Flowers FP, Fang T: Distant cancer effects on standardised testing of peripheral vision. Br J Ophthalmol; 2001 Mar;85(3):291-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Profound central-retinal visual losses have been a major presenting factor reported in cancer and melanoma associated retinopathies (CAR, MAR).
  • However, it is well established that standardised tests of peripheral retinal function are often the most sensitive detectors of early eye disease.
  • This is a preliminary investigation of the responsiveness of the peripheral retina to "distant" (non-eye or CNS) cancers using easily obtained standardised tests.
  • RESULTS: 98% (49 of 50) of eyes from the patient cohort were judged clinically normal following examinations which emphasised the central retina, fundus appearance, and static fields.
  • These abnormalities clustered mainly about dark adaptation (rod cell) sensitivity (31, 62% of measured sites), the blue sensitive retinal cells (17, 34% of measured eyes), and the oscillatory component (OP) of the electroretinogram (23, 46% of measured eyes).
  • There was no identifiable interaction between chemotherapy mode and the cancer associated retinal deficits (CARD).
  • CONCLUSION: CARD is common in the retinal periphery of many cancer patients, and is distinct from rare CAR, MAR central-retinal responses.
  • [MeSH-major] Breast Neoplasms / complications. Lung Neoplasms / complications. Melanoma / complications. Vision, Low / etiology
  • [MeSH-minor] Adaptation, Ocular / physiology. Adult. Aged. Analysis of Variance. Antineoplastic Agents / therapeutic use. Autoantibodies / blood. Case-Control Studies. Color Perception Tests. Electroretinography. Female. Humans. Male. Middle Aged. Reference Values. Retina / immunology. Single-Blind Method. Visual Acuity. Visual Field Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vision Res. 1971;Suppl 3:129-49 [5293866.001]
  • [Cites] Arch Ophthalmol. 1987 Jun;105(6):810-4 [3579713.001]
  • [Cites] Acta Ophthalmol (Copenh). 1989 Apr;67(2):113-8 [2728861.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1589-94 [2555714.001]
  • [Cites] Ophthalmology. 1992 Aug;99(8):1286-95 [1325045.001]
  • [Cites] Br J Ophthalmol. 1992 Aug;76(8):461-4 [1390526.001]
  • [Cites] Arch Ophthalmol. 1992 Nov;110(11):1571-6 [1444914.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Jan;34(1):91-100 [8425845.001]
  • [Cites] Arch Ophthalmol. 1993 Mar;111(3):350-6 [8447745.001]
  • [Cites] Arch Ophthalmol. 1993 Jul;111(7):931-7 [8392327.001]
  • [Cites] Doc Ophthalmol. 1993;84(3):237-46 [8119103.001]
  • [Cites] Exp Eye Res. 1994 Oct;59(4):447-55 [7859820.001]
  • [Cites] Doc Ophthalmol. 1995;89(3):199-210 [7555587.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):1018-26 [8622006.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Feb;78(2):120-9 [8625554.001]
  • [Cites] Optom Vis Sci. 1995 Dec;72(12):907-10 [8749339.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1419-22 [8912538.001]
  • [Cites] Eye (Lond). 1997;11 ( Pt 3):295-7 [9373465.001]
  • [Cites] Am J Ophthalmol. 1998 Apr;125(4):493-501 [9559735.001]
  • [Cites] Am J Ophthalmol. 1998 Aug;126(2):296-302 [9727525.001]
  • [Cites] J Opt Soc Am. 1952 Aug;42(8):509-21 [14946611.001]
  • [Cites] Ann Hum Genet. 1955 Aug;20(1):39-56 [13249225.001]
  • [Cites] Vision Res. 1970 May;10(5):423-33 [5312357.001]
  • [Cites] Acta Ophthalmol (Copenh). 1974;52(3):307-16 [4546835.001]
  • [Cites] Acta Ophthalmol (Copenh). 1980 Dec;58(6):865-78 [7331773.001]
  • [Cites] J Immunol. 1982 Jun;128(6):2779-87 [6176652.001]
  • [Cites] Am J Ophthalmol. 1982 May;93(5):635-42 [6979252.001]
  • [Cites] Acta Ophthalmol (Copenh). 1982 Dec;60(6):907-16 [6984998.001]
  • [Cites] Am J Ophthalmol. 1984 Mar;97(3):277-87 [6322591.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1984 Jul;25(7):787-94 [6329990.001]
  • [Cites] Arch Ophthalmol. 1984 Sep;102(9):1307-11 [6383303.001]
  • [Cites] Arch Ophthalmol. 1987 Mar;105(3):372-5 [2950846.001]
  • [Cites] Am J Ophthalmol. 1988 Sep 15;106(3):307-11 [2971322.001]
  • (PMID = 11222333.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Autoantibodies
  • [Other-IDs] NLM/ PMC1723897
  •  go-up   go-down


6. Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F: Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene; 2001 Mar 22;20(12):1403-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the retina, angiogenesis is an important component of normal physiological events such as embryonic vascular development.
  • It is also involved in pathological processes including diabetic retinopathies and age-related macular degeneration, and tumour growth such as choroidal melanoma.
  • Fibroblast growth factor (FGF) 2 and vascular endothelial cell growth factor (VEGF) are the two major angiogenic factors in the retina.
  • Pharmacological inhibition of Ras processing, and of MEK1 and ERK1/2 activation reduced only by 50% FGF2-induced cell proliferation, suggesting that there is another signalling pathway for CEC proliferation.
  • Pharmacological inhibition of the PI 3-Kinase also inhibits by half FGF2-induced CEC proliferation.
  • These data on the molecular mechanism and signalling may have important implications for providing more selective methods for anti-angiogenic and anti-tumoural therapy.
  • [MeSH-minor] Animals. Cattle. Cell Division. Dose-Response Relationship, Drug. Immunomagnetic Separation. Mitogen-Activated Protein Kinase 1. Mitogen-Activated Protein Kinase 3. Mitogen-Activated Protein Kinases / metabolism. Mitogens / pharmacology. Models, Biological. Neovascularization, Physiologic. Phosphatidylinositol 3-Kinases / metabolism. Receptor Cross-Talk. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors


7. Jacobzone C, Cochard-Marianowski C, Kupfer I, Bettembourg S, Dordain Y, Misery L, Cochener B, Sassolas B: Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol; 2004 Oct;140(10):1258-61
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings.
  • BACKGROUND: Visual disturbance in the course of melanoma is rare.
  • Specific localized metastases and drug toxic effects are frequently the cause.
  • Recognition of a retinopathy raises several questions when the diagnosis of melanoma-associated retinopathy (MAR) can be confirmed.
  • Descriptions of such patients in dermatologic literature are rare and deserve attention because therapeutic decisions are mandatory.
  • OBSERVATIONS: A 70-year-old woman had a first melanoma in 1985 and a second primary melanoma in 1994.
  • Axillary lymph node involvement occurred in November 2000, leading to surgery and chemotherapy.
  • Computed tomography and cerebral magnetic resonance imaging ruled out localized tumor on the eyes or optic nerves or evolution of disease.
  • Ophthalmologic examination revealed a bilateral posterior uveitis, with hyalitis and progressive destruction of retinal pigment.
  • The electrophysiologic data confirmed the diagnosis of MAR.
  • Symptoms improved after systemic corticosteroid therapy, with no relapse after tapering doses despite worsening of melanoma.
  • Also, MAR is linked to the presence of autoantibodies directed against melanoma antigens that cross-react with the rod bipolar cells of the retina.
  • Corticosteroid therapy is rarely beneficial.
  • Our case of MAR is noteworthy because it involved a woman, was associated with an uveitis, and improved with corticosteroid therapy.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Melanoma / complications. Retinal Diseases / diagnosis. Retinal Diseases / drug therapy. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Electrophysiology. Female. Humans. Neoplasms, Second Primary / complications. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / drug therapy. Paraneoplastic Syndromes / etiology. Vision, Low / diagnosis. Vision, Low / drug therapy. Vision, Low / etiology. Visual Acuity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492190.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


8. Ockenfels M, Lisch W: [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review]. Hautarzt; 2003 Feb;54(2):144-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
  • BACKGROUND AND OBJECTIVE: In dermatology, interferon Alfa 2 is used in adjuvant therapy of melanoma (stage IIa/b) as well as in treatment of cutaneous lymphoma or melanoma (stage III or higher).
  • We wondered if incidence and prognosis of ocular complications were elevated in patients receiving an adjuvant treatment of melanoma with interferons.
  • More than the half of these patients developed significant visual loss including retinal ischemia.
  • CONCLUSIONS: These data underscore the importance to inform patients concerning ocular adverse effects and emphasize the need to monitor the retina during adjuvant interferon therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Eye Diseases / chemically induced. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Recombinant Proteins. Retinal Diseases / chemically induced. Retinal Diseases / diagnosis. Vision Disorders / chemically induced. Vision Disorders / diagnosis

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12590309.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 15
  •  go-up   go-down


9. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES: Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology; 2009 Nov;116(11):2206-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
  • PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after radiation or enucleation reduces death rates in patients with uveal melanoma.
  • METHODS: Between May 1995 and June 1999, 121 patients with choroidal or ciliary body melanoma began a 2-year course of therapy (3 MIU IFN-alfa-2a subcutaneously 3 times per week), initiated within 3 years of primary therapy.
  • All patients underwent regular monitoring for drug toxicity.
  • To evaluate IFN-alfa-2a efficacy, we selected a series of historical controls frequency-matched (2:1) to IFN-alfa-2a-treated patients on age (+/-5 years), LTD (+/-3 mm), gender, and survival time between primary therapy and initiation of IFN therapy.
  • MAIN OUTCOME MEASURES: Melanoma-related mortality, metastasis, IFN-related toxicities.
  • RESULTS: Fifty-five patients (45%) completed therapy; the median dose for IFN-alfa-2a-treated patients was 792 MIU (85% of the theoretic dose).
  • The median follow-up time in the IFN-alfa-2a-treated group was approximately 9 years.
  • Treatment and control groups were similar with respect to age (P = 0.78), LTD (P = 0.38), and gender (P = 1.0).
  • Of 363 patients, 108 developed metastasis under observation; 42 of these were IFN-alfa-2a-treated patients.
  • Cumulative 5-year melanoma-related death rates were 17% in the radiation or enucleation-only group, 15% in those who completed the entire IFN-alfa-2a course, and 35% in those who discontinued IFN-alfa-2a therapy.
  • In multivariate Cox regression, IFN-alfa-2a had no significant influence on melanoma-related mortality (rate ratio = 1.02, 95% confidence interval, 0.68-1.5, P = 0.91) or all-cause mortality (rate ratio = 0.84, 95% confidence interval, 0.58-1.2, P = 0.34).
  • CONCLUSIONS: Interferon-alfa-2a has no material influence on survival in patients with choroidal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Eye Enucleation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Recombinant Proteins. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2010 Sep;117(9):1861 [20816255.001]
  • (PMID = 19744725.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


10. Freudenstein D, Wagner A, Bornemann A, Ernemann U, Bauer T, Duffner F: Primary melanocytic lesions of the CNS: report of five cases. Zentralbl Neurochir; 2004;65(3):146-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary melanocytic tumours of the central nervous system (CNS) form a rare entity which is histologically and clinically distinct from metastatic cutaneous or retinal malignant melanoma.
  • They can be classified into diffuse melanocytosis (diffuse melanosis), malignant melanoma and benign melanocytoma with a small number of intermediate variants.
  • In this paper, 5 cases treated neurosurgically in our department for spinal or cerebral primary CNS malignant melanoma are reported.
  • Compared to metastatic disease, primary CNS malignant melanoma shows a more benign clinical course with long-term tumour control and a good quality of life.
  • Although therapeutic experience for primary melanocytic lesions of the CNS is based on a small number of published cases, prognosis seems highly dependent on complete tumour resection.
  • Adjuvant radiation seems to be of additional therapeutic benefit.
  • Except for meningeosis melanomatosa chemotherapy must be regarded as experimental.
  • Unfortunately, a standardised therapy concept is still lacking.
  • [MeSH-major] Brain Neoplasms / surgery. Melanocytes / pathology. Melanoma / surgery. Neurosurgical Procedures. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15306980.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Lederman M, Meir T, Zeschnigk M, Pe'er J, Chowers I: Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma. Curr Eye Res; 2008 Oct;33(10):876-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma.
  • PURPOSE: Members of the inhibitors of apoptosis proteins (IAPs) family are thought to promote tumor growth and interfere with response to therapy by suppressing apoptosis in several malignancies.
  • We aimed to evaluate the expression of IAPs in uveal melanoma (UM) and its correlation with prognostic factors associated with death from metastatic UM.
  • QPCR results were correlated with apoptosis rate and with prognostic factors in UM, including lesion dimensions, cell type, monosomy 3, and vascular mimicry patterns.
  • BIRC5 and BIRC7 levels were 8.8-fold (p = 0.0003) and 7.0-fold (p = 0.003) higher in tumors (primary and metastatic tissue) vs. normal eye tissue, respectively.
  • BIRC5 levels correlated with presence of monosomy 3 (p = 0.01) and higher levels of BIRC7 correlated with epithelioid cell type (p = 0.048).
  • Considering our findings together with previous reports on their role in a variety of malignancies and in UM cell lines, it is conceivable that IAPs contribute to the remarkable resistance of uveal melanoma to apoptosis-inducing chemotherapy.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Inhibitor of Apoptosis Proteins / genetics. Liver Neoplasms / genetics. Melanoma / genetics. Uveal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / genetics. Cell Line, Tumor. Choroid / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 3 / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retina / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853322.001).
  • [ISSN] 1460-2202
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins
  •  go-up   go-down


12. Mason JO 3rd, Albert MA Jr, Persaud TO, Vail RS: Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina; 2007 Sep;27(7):903-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
  • PURPOSE: To evaluate the effect of intravitreal bevacizumab treatment on patients with macular edema (ME) due to radiation retinopathy after plaque radiotherapy for choroidal melanoma.
  • METHODS: In this retrospective case series, 10 consecutive patients with ME due to radiation retinopathy after plaque radiotherapy for choroidal melanoma were treated with a single intravitreal injection of bevacizumab.
  • Postinjection best-corrected visual acuity (BCVA) and mean foveal thickness measured by ocular coherence tomography were the primary outcome measures.
  • RESULTS: The mean BCVA at the time of the diagnosis of choroidal melanoma was 20/25 (range, 20/20 to 20/40).
  • Radiation ME developed at a mean of 26 months (range, 17-44 months) after plaque radiotherapy.
  • Choroidal melanoma regressed in all patients, and there were no neovascular sequelae.
  • At the time of radiation ME diagnosis, the mean BCVA was 20/100 (range, 20/40 to 20/200).
  • Mean foveal thickness measured by ocular coherence tomography was 482 microm before injection, 284 microm 6 weeks after injection, and 449 mum 4 months after injection.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Macular Edema / drug therapy. Melanoma / radiotherapy. Radiation Injuries / drug therapy. Retina / radiation effects
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Fluorescein Angiography. Humans. Injections. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Visual Acuity. Vitreous Body

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891015.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


13. Shields CL, Demirci H, Dai V, Marr BP, Mashayekhi A, Materin MA, Manquez ME, Shields JA: Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina; 2005 Oct-Nov;25(7):868-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma.
  • OBJECTIVE: To evaluate the effect of intravitreal triamcinolone acetonide on patients with visually symptomatic radiation-induced maculopathy after plaque radiotherapy for choroidal melanoma.
  • DESIGN: In this prospective, nonrandomized, single-center case series of 31 patients with visually symptomatic radiation-induced maculopathy after plaque radiotherapy for choroidal melanoma at the Ocular Oncology Service at Wills Eye Hospital of Thomas Jefferson University, triamcinolone acetonide (4 mg/1 mL) was injected through the pars plana into the vitreous cavity using sterile technique.
  • RESULTS: At the time of diagnosis of choroidal melanoma, visual acuity was 20/20 to 20/50 in 90% (n = 28), 20/60 to 20/200 in 10% (n = 3), and 20/400 or worse in none of the patients.
  • Radiation maculopathy developed at a mean of 22 months (median, 16 months; range, 6-96 months) after plaque radiotherapy.
  • In all cases, the choroidal melanoma was regressed, and there was no retinal detachment or neovascularization of the retina, optic disk, or iris.
  • At the time of diagnosis of radiation maculopathy, visual acuity was 20/20 to 20/50 in 19% (6/31), 20/60 to 20/200 in 58% (18/31), and 20/400 or worse in 23% (7/31) of patients.
  • Mean foveal thickness by optical coherence tomography was 417 microm at injection and 207 microm at 1 month and 292 microm at 6 months after injection.
  • [MeSH-major] Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Glucocorticoids / therapeutic use. Melanoma / radiotherapy. Radiation Injuries / drug therapy. Retina / radiation effects. Retinal Diseases / drug therapy. Triamcinolone Acetonide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Injections. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Tomography, Optical Coherence. Visual Acuity. Vitreous Body


14. Subhadra C, Dudek AZ, Rath PP, Lee MS: Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol; 2008 Mar;28(1):23-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin.
  • Melanoma-associated retinopathy (MAR) is a rare disorder characterized by photopsias, shimmering vision, nyctalopia, and dysfunction of rod photoreceptor cells.
  • We describe a 56-year-old man with metastatic cutaneous melanoma to the lymph nodes and MAR.
  • He underwent resection of the metastasis followed by radiation therapy.
  • Our patient indicates that even after a reduction or elimination of melanoma tumor burden and presumably the attenuation of the antigenic stimulus driving MAR, this disorder can continue to progress.
  • In this setting, IVIg therapy should be considered a viable treatment option.
  • [MeSH-major] Immunoglobulins, Intravenous / administration & dosage. Melanoma / complications. Paraneoplastic Syndromes, Nervous System / drug therapy. Paraneoplastic Syndromes, Nervous System / physiopathology. Retinal Diseases / drug therapy. Retinal Diseases / physiopathology
  • [MeSH-minor] Autoantibodies / drug effects. Autoantibodies / immunology. Disease Progression. Electroretinography. Humans. Immunotherapy / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy. Retina / drug effects. Retina / immunology. Retina / physiopathology. Retinal Bipolar Cells / drug effects. Retinal Bipolar Cells / immunology. Retinal Bipolar Cells / pathology. Treatment Outcome. Vision, Low / drug therapy. Vision, Low / immunology. Vision, Low / physiopathology. Visual Fields / drug effects. Visual Fields / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347454.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


15. Di Nicolantonio F, Neale M, Onadim Z, Hungerford JL, Kingston JL, Cree IA: The chemosensitivity profile of retinoblastoma. Recent Results Cancer Res; 2003;161:73-80
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoblastoma is a rare malignant tumour of the developing retina with an incidence of 1 in 20,000 live births in all human races.
  • Chemotherapy is used in retinoblastoma as adjuvant therapy to prevent the growth of metastases and to treat metastatic disease once this has become clinically apparent.
  • Current regimens are based on empirical drug combinations, and few clinical trials have been conducted because of the rarity of this tumour.
  • The ATP-based chemosensitivity assay (ATP-TCA) has already helped to design new regimens for melanoma and breast and ovarian cancer.
  • These data confirm that retinoblastoma is a rapidly growing malignancy that is very susceptible to cytotoxic drugs of all types.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Screening Assays, Antitumor / methods. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Child, Preschool. Drug Resistance, Neoplasm. Female. Humans. Infant. Male. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12528800.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


16. Diebold Y, Calonge M: Applications of nanoparticles in ophthalmology. Prog Retin Eye Res; 2010 Nov;29(6):596-609
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nanocarriers, such as nanoparticles, have the capacity to deliver ocular drugs to specific target sites and hold promise to revolutionize the therapy of many eye diseases.
  • One of the most important handicaps of the eye as a target organ for drugs is the presence of several barriers that impede direct and systemic drug access to the specific site of action.
  • Superficial barriers include the ocular surface epithelium and the tear film, and internal barriers include the blood-aqueous and blood-retina barriers.
  • Topical application is the preferred route for most drugs, even when the target tissues are at the back part of the eye where intraocular injections are currently the most common route of administration.
  • Direct administration using any of these two routes faces many problems related to drug bioavailability, including side effects and repeated uncomfortable treatments to achieve therapeutic drug levels.
  • In this regard, the advantages of using nanoparticles include improved topical passage of large, poorly water-soluble molecules such as glucocorticoid drugs or cyclosporine for immune-related, vision-threatening diseases.
  • Other large and unstable molecules, such as nucleic acids, delivered using nanoparticles offer promising results for gene transfer therapy in severe retinal diseases.
  • Also, nanoparticle-mediated drug delivery increases the contact time of the administered drug with its target tissue, such as in the case of brimonidine, one of the standard treatments for glaucoma, or corticosteroids used to treat autoimmune uveitis, a severe intraocular inflammatory process.
  • In addition, nanocarriers permit the non-steroidal anti-inflammatory drug indomethacin to reach inner eye structures using the transmucosal route.
  • Finally, nanoparticles allow the possibility of targeted delivery to reach specific types of cancer, such as melanoma, leaving normal cells untouched.
  • This review summarizes experimental results from our group and others since the beginnings of nanocarrier technology to deliver drugs to different locations in the eye.
  • Also, it explores the future possibilities of nanoparticles not only as drug delivery systems but also as aides for diagnostic purposes.
  • [MeSH-major] Nanoparticles / therapeutic use. Ophthalmology. Retinal Diseases / therapy
  • [MeSH-minor] Animals. Drug Delivery Systems / methods. Humans

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20826225.001).
  • [ISSN] 1873-1635
  • [Journal-full-title] Progress in retinal and eye research
  • [ISO-abbreviation] Prog Retin Eye Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


17. Risard SM, Pieramici DJ, Rabena MD: Cystoid macular edema secondary to Paclitaxel (abraxane). Retin Cases Brief Rep; 2009;3(4):383-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 58-year-old man with Stage 4 metastatic cutaneous melanoma presented with decreased vision and macular edema while having minimal fluorescein leakage 7 months into a course of paclitaxel chemotherapy.
  • The edema continued to worsen, and vision declined until paclitaxel therapy was discontinued.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25389854.001).
  • [ISSN] 1935-1089
  • [Journal-full-title] Retinal cases & brief reports
  • [ISO-abbreviation] Retin Cases Brief Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lang GE, Mennel S, Spital G, Wachtlin J, Jurklies B, Heimann H, Damato B, Meyer CH: [Different indications of photodynamic therapy in ophthalmology]. Klin Monbl Augenheilkd; 2009 Sep;226(9):725-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Different indications of photodynamic therapy in ophthalmology].
  • [Transliterated title] Verschiedene Indikationen der photodynamischen Therapie in der Augenheilkunde.
  • BACKGROUND: Photodynamic therapy (PDT) in eye disease was approved 10 years ago for age-related macular degeneration (AMD).
  • The treatment regimen is based on two prospective, multicentre trials (TAP and VIP studies).
  • Different diseases and their treatment with PDT are discussed.
  • RESULTS: The treatments of idiopathic CNV, secondary CNV in inflammatory diseases of the retina and choroid, choroidal haemangioma, vasoproliferative tumours, malignant melanoma of the choroid, and central serous chorioretinopathy with PDT are described.
  • In most patients the disease progression can be stopped and in some the PDT treatment results in visual improvement.
  • The prognosis is better in patients with early disease detection and small lesions.
  • CONCLUSION: Several retinal and choroidal diseases can be treated successfully with PDT.
  • Except for AMD and pathological myopia, PDT is an off label treatment.
  • [MeSH-major] Choroid Diseases / drug therapy. Ophthalmic Solutions / therapeutic use. Ophthalmology / trends. Photochemotherapy / trends. Photosensitizing Agents / therapeutic use. Retinal Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603375.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ophthalmic Solutions; 0 / Photosensitizing Agents
  • [Number-of-references] 60
  •  go-up   go-down


19. Finger PT: Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):974-7
Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report on bevacizumab treatment for radiation retinopathy affecting the macula.
  • Treatment involved intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) every 6-12 weeks.
  • Treatment was discontinued at patient request or if there was no measurable response to therapy.
  • Main outcome measures included best corrected visual acuity, ophthalmic examination, retinal photography, and angiography.
  • RESULTS: Bevacizumab treatment was followed by reductions in retinal hemorrhage, exudation, and edema.
  • Three patients discontinued therapy.
  • Each was legally blind before treatment (n=1), experienced little to no subjective improvement (n=2), or was poorly compliant (n=2).
  • In most cases treatment was associated with decreased vascular leakage, stabilization, or improved vision.
  • An anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Radiation Injuries / drug therapy. Retina / radiation effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Choroid Neoplasms / radiotherapy. Humans. Injections / methods. Melanoma / radiotherapy. Middle Aged. Palladium / therapeutic use. Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313522.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Radioisotopes; 2S9ZZM9Q9V / Bevacizumab; 5TWQ1V240M / Palladium
  •  go-up   go-down


20. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol; 2002 Sep;240(9):748-57
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.
  • PURPOSE: To determine the effects of photodynamic therapy (PDT) on choroidal and retinal structures of human eyes.
  • METHODS: One eye from each of three patients with large malignant melanomas of the uvea destined for enucleation received PDT using verteporfin according to the approved treatment recommendations for patients with age-related macular degeneration.
  • RESULTS: In agreement with the clinical angiographic findings of hypofluorescence, a rather selective occlusion of the choriocapillary layer was observed in the 50-J/cm(2) PDT areas, whereas the 100-J/cm(2) PDT areas additionally revealed closure of deeper choroidal vessels and focal alterations of the retinal pigment epithelium.
  • The overlying neurosensory retina, including photoreceptors and retinal capillaries, was well preserved in all PDT areas.
  • CONCLUSIONS: PDT with verteporfin at a dosage used clinically induces selective occlusion of the physiological choriocapillaris without affecting deeper choroidal, retinal, and optic nerve vessels or the overlying retinal pigment epithelium and neurosensory retina.
  • An increase in light dose enhances the occlusive effect with thrombosis within deeper choroidal layers and damage to the retinal pigment epithelium.
  • [MeSH-major] Choroid / drug effects. Melanoma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retina / drug effects. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Arterial Occlusive Diseases / chemically induced. Arterial Occlusive Diseases / pathology. Capillaries / drug effects. Capillaries / ultrastructure. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Prospective Studies. Retinal Vessels / drug effects. Retinal Vessels / ultrastructure

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12271373.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


21. Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U: Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clin Exp Ophthalmol; 2007 Dec;35(9):878-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection.
  • Neovascular glaucoma is a serious complication arising from irradiation of uveal melanoma.
  • Treatment options include panretinal photocoagulation, peripheral retina cryotherapy, photodynamic therapy with verteporfin, triamcinolone injections and surgical removal of the dying tumour mass.
  • The authors describe a case report of a radiation-induced neovascular glaucoma and exudative retinal detachment caused by malignant melanoma of the uvea that was treated with intravitreal ranibizumab.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Exudates and Transudates / metabolism. Glaucoma, Neovascular / drug therapy. Glaucoma, Neovascular / etiology. Radiation Injuries / complications. Retinal Detachment / drug therapy. Retinal Detachment / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Humans. Injections. Ranibizumab. Vitreous Body

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173426.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down


22. Shields CL, Demirci H, Marr BP, Mashayekhi A, Dai VV, Materin MA, Shields JA: Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina; 2006 May-Jun;26(5):537-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In a prospective, nonrandomized, single-center case series, intravitreal triamcinolone acetonide (4 mg/0.1 mL) was injected through the pars plana using sterile technique in 9 patients with radiation papillopathy after plaque radiotherapy for choroidal melanoma.
  • RESULTS: At the time of diagnosis of the choroidal melanoma, visual acuity was 20/20 to 20/40 (n = 6), 20/60 (n = 2), and 20/100 (n = 1).
  • Radiation papillopathy developed a mean of 18 months (median, 17 months; range, 6-33 months) after plaque radiotherapy.
  • In all cases, the choroidal melanoma was regressed, and there was no retinal detachment or neovascularization of the retina, optic disk, or iris.
  • At the time of diagnosis of radiation papillopathy, visual acuity was 20/70 (n = 1), 20/100 (n = 4), 20/200 (n = 1), and counting fingers (n = 3).
  • The mean time to improvement in visual acuity by > or =2 lines was 3 weeks (median, 1 week; range, 1-12 weeks).
  • The mean time to complete resolution of radiation papillopathy was 4 months.
  • The two patients with worse final visual acuity also had macular hole and central retinal vein obstruction.
  • The only complication of this therapy was possibly related cataract in three patients.
  • [MeSH-major] Brachytherapy / adverse effects. Glucocorticoids / therapeutic use. Optic Disk / radiation effects. Optic Nerve Diseases / drug therapy. Radiation Injuries / drug therapy. Retinal Diseases / drug therapy. Triamcinolone Acetonide / therapeutic use
  • [MeSH-minor] Acute Disease. Adult. Aged. Choroid Neoplasms / radiotherapy. Female. Humans. Injections. Iodine Radioisotopes / adverse effects. Male. Melanoma / radiotherapy. Middle Aged. Prospective Studies. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770260.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Iodine Radioisotopes; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down


23. Gupta A, Muecke JS: Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina; 2008 Jul-Aug;28(7):964-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
  • PURPOSE: To evaluate the safety and efficacy of intravitreal injection of bevacizumab as a treatment option for radiation maculopathy secondary to plaque radiotherapy.
  • METHODS: Interventional case series of five patients who developed radiation maculopathy complicating plaque radiotherapy with ruthenium 106 for choroidal melanoma.
  • The main outcome measures were visual acuity and results of clinical ophthalmic examination and optical coherence tomography.
  • The average preinjection central macular thickness measured by optical coherence tomography was 351 microm.
  • Three of five patients had no improvement in macular edema after treatment with a single injection of bevacizumab at the 2-week follow-up (average postinjection central macular thickness, 287 microm).
  • Maculopathy in these two patients was diagnosed 1 week before treatment was offered.
  • CONCLUSIONS: In this series, treatment of radiation maculopathy with intravitreal injection of bevacizumab was useful in two patients as measured by improvement in visual acuity due to resolution of macular edema.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Macula Lutea / radiation effects. Radiation Injuries / drug therapy. Retinal Diseases / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Female. Follow-Up Studies. Humans. Injections. Male. Melanoma / radiotherapy. Middle Aged. Retreatment. Retrospective Studies. Ruthenium Radioisotopes / adverse effects. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698298.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Ruthenium Radioisotopes; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


24. Jacobson DM, Adamus G: Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol; 2001 Jun;131(6):806-8
MedlinePlus Health Information. consumer health - Retinal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma.
  • PURPOSE: To describe clinical, electrophysiologic, and immunologic features of a unique paraneoplastic retinopathy with characteristics of cancer-associated and melanoma-associated retinopathy.
  • METHODS: Serial assessment of clinical visual function, electroretinography, and assays of anti-retinal antibodies.
  • RESULTS: A 51-year-old woman with progressive visual glare for 1 year had normal visual acuity and color vision, paracentral scotomas, and a normal-appearing retina.
  • Several months after resection of the tumor and chemotherapy, no evidence existed of cancer or anti-bipolar cell antibodies, and electroretinography responses were markedly improved.
  • CONCLUSION: The presence of anti-bipolar cell antibodies in a patient with retinal dysfunction is not specific of melanoma-associated retinopathy.
  • Effective treatment of cancer may result in elimination of associated anti-retinal antibodies and improved retinal function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11384586.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY013053; United States / NEI NIH HHS / EY / EY 13053
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


25. Finger PT, Chin K: Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. Arch Ophthalmol; 2007 Jun;125(6):751-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: After plaque radiation therapy, 6 patients developed radiation retinopathy (retinal edema, hemorrhages, microangiopathy, and neovascularization).
  • Ophthalmic evaluations included visual acuity, ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO) imaging.
  • RESULTS: No bevacizumab-related ocular or systemic adverse effects have occurred within the first 8 months of therapy.
  • Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and microangiopathy were documented by photography, angiography, and OCT/SLO imaging.
  • CONCLUSIONS: Intravitreal bevacizumab was tolerated, improved or maintained vision, and reduced hemorrhage and retinal edema (angiographic leakage).
  • This study should lead to additional and longer-term studies of humanized monoclonal anti-vascular endothelial growth factor antibody therapy for radiation retinopathy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Radiation Injuries / drug therapy. Retina / radiation effects. Retinal Diseases / drug therapy. Vascular Endothelial Growth Factor A
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Female. Fluorescein Angiography. Humans. Male. Melanoma / radiotherapy. Middle Aged. Ophthalmoscopy. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562985.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


26. Davidorf FH, Mouser JG, Derick RJ: Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina; 2006 Mar;26(3):354-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Glaucoma, Neovascular / drug therapy. Iris / blood supply. Iris Diseases / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Choroid Neoplasms / pathology. Fluorescein Angiography. Fluorophotometry. Humans. Injections. Male. Melanoma / pathology. Middle Aged. Vascular Endothelial Growth Factor A / immunology. Visual Acuity. Vitreous Body

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508439.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


27. Cantrill HL, Pulido JS, Donaldson M, Shields CL, Murray TG: Diagnostic and therapeutic challenges. Retina; 2008 Jul-Aug;28(7):1018-22
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic challenges.
  • [MeSH-major] Choroid Neoplasms / ultrasonography. Melanoma / ultrasonography
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Eye Enucleation. Female. Fluorescein Angiography. Humans. Lymphatic Metastasis. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Parotid Neoplasms / drug therapy. Parotid Neoplasms / pathology. Rituximab

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698308.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Querques G, Prascina F, Iaculli C, Delle Noci N: Intravitreal pegaptanib sodium (Macugen) for radiation retinopathy following episcleral plaque radiotherapy. Acta Ophthalmol; 2008 Sep;86(6):700-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aptamers, Nucleotide / therapeutic use. Brachytherapy / adverse effects. Optic Disk / blood supply. Radiation Injuries / drug therapy. Retina / radiation effects. Retinal Neovascularization / drug therapy
  • [MeSH-minor] Choroid Neoplasms / radiotherapy. Exudates and Transudates. Female. Fluorescein Angiography. Humans. Injections. Melanoma / radiotherapy. Middle Aged. Retinal Hemorrhage / diagnosis. Retinal Hemorrhage / drug therapy. Retinal Hemorrhage / etiology. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vitreous Body

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705681.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Vascular Endothelial Growth Factor A; 0 / pegaptanib
  •  go-up   go-down


29. Garcia-Arumi J, Morral Palau M, Montolio Gil M, Blasco Garrido H, Sararols Ramsay L, Segura García A: Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma. Br J Ophthalmol; 2006 Apr;90(4):516-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Choroidal Neovascularization / chemically induced. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2000 Apr;118(4):580-2 [10766150.001]
  • [Cites] Am J Ophthalmol. 2001 Jun;131(6):782-7 [11384576.001]
  • [Cites] Arch Ophthalmol. 2001 Jul;119(7):1077-9 [11448335.001]
  • [Cites] Retina. 2003 Aug;23(4):546-8 [12972771.001]
  • [Cites] Br J Ophthalmol. 1998 Mar;82(3):323-5 [9602634.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2054-6 [7942735.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] Am J Gastroenterol. 1996 Feb;91(2):309-13 [8607498.001]
  • [Cites] J Neuroophthalmol. 2003 Dec;23(4):256-9 [14663304.001]
  • (PMID = 16547342.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Other-IDs] NLM/ PMC1857019
  •  go-up   go-down


30. Nicolo M, Calabria G: Choroidal metastasis from a cutaneous malignant melanoma regressed after cisplatin therapy. Retina; 2004 Aug;24(4):622-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis from a cutaneous malignant melanoma regressed after cisplatin therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Cisplatin / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15300090.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Ziemssen F, Voelker M, Altpeter E, Bartz-Schmidt KU, Gelisken F: Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol Scand; 2007 Aug;85(5):579-80
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Melanoma / radiotherapy. Radiation Injuries / drug therapy. Retina / radiation effects
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Fluorescein Angiography. Humans. Injections. Male. Middle Aged. Ruthenium Radioisotopes / adverse effects. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vitreous Body

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324216.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Ruthenium Radioisotopes; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


32. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO: Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol; 2002 Jun;120(6):835-44
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological changes following photodynamic therapy in human eyes.
  • [MeSH-major] Choroid / pathology. Photochemotherapy. Photosensitizing Agents / therapeutic use. Pigment Epithelium of Eye / pathology. Porphyrins / therapeutic use. Retina / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Choroidal Neovascularization / drug therapy. Choroidal Neovascularization / pathology. Endothelium, Vascular / pathology. Endothelium, Vascular / ultrastructure. Eye Enucleation. Female. Fluorescein Angiography. Humans. Indocyanine Green. Macular Degeneration / drug therapy. Macular Degeneration / pathology. Male. Melanoma / surgery. Retinal Vessels / pathology. Retinal Vessels / ultrastructure. Uveal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12049594.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down






Advertisement